Please assess the completion status of the following clinical trial:

Trial Title: Lifestyle Modification and Metformin Use in the Treatment of HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤ 65 years of age~* HIV positive, on a stable combination antiretroviral regimen for \> 6 months, including but not limited to either 2 nucleoside reverse transcriptase inhibitors (NRTI) and a non-nucleoside reverse transcriptase inhibitors (NNRTI) or protease inhibitor (PI), or a triple NRTI regimen~* Ability and motivation to modify behavior and make lifestyle changes~* NCEP-Adult Treatment Panel III defined metabolic syndrome, as defined by 3 out of 5 of the following: 1) Waist circumference greater than 102 cm (40 in) in men and 88 cm (35 in) in women, 2) Triglycerides ≥ 150 mg/dL or current anti-lipolytic drug treatment, 3) high-density lipoprotein less than 40mg/dL in men and 50 mg/dL in women, 4) Blood pressure ≥ 130/85 mmHg or current antihypertensive drug treatment, 5) Fasting glucose ≥ 100 mg/dL~Exclusion Criteria:~* Any new serious opportunistic infection within the past 6 weeks~* History of unstable angina, aortic stenosis, uncontrolled hypertension, severe neuropathy, arthritis or other contraindication to exercise~* Current therapy with insulin or other diabetic agent, fasting blood sugar \> 126~* Requiring parenteral nutrition or parenteral glucocorticoid therapy or oral glucocorticoid therapy~* Estrogen, progestational derivative, or ketoconazole use within 3 months~* New antiretroviral regimen in the past 6 months~* Serum creatinine \> 1.5 mg/dL (males) and 1.4 mg/dL (females), serum glutamic pyruvic transaminase-liver function (SGPT), \> 2.5 upper limit of normal (ULN), Lactate \> 2.0 ULN, hemoglobin \< 10.0 mg/dL~* Current substance and/or alcohol abuse~* Known hypersensitivity to Metformin~* Congestive heart failure requiring pharmacologic treatment~* Use of cimetidine or planned use during the study period~* Hypertrophic obstructive cardiomyopathy~* Pregnant or actively seeking pregnancy, breastfeeding~* Testosterone use for non-physiologic purposes, or physiologic testosterone replacement for \< 3 months.~* Presence of active AIDS including cancers~* Current viral, bacterial or other infections (excluding HIV)~* Weight loss in the past 3 months of greater than 10 pounds~* Nitrates or other medications that can alter endothelial function~* Contraindication to beta blocker or nitroglycerin use~* Patients with previous allergic reactions to iodine-containing contrast media or to iodine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: PLACEBO_COMPARATOR): No Lifestyle Modification and Placebo
- Group 2 (Type: ACTIVE_COMPARATOR): Lifestyle Modification and Placebo
- Group 3 (Type: ACTIVE_COMPARATOR): No Lifestyle Modification and Metformin
- Group 4 (Type: ACTIVE_COMPARATOR): Lifestyle Modification and Metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete